500702-97-6

Basic information

• Product Name: R-N-Cbz-2-Hydroxymethylmorpholine
• Synonyms: R-N-Cbz-2-Hydroxymethylmorpholine;(2R)-2-(Hydroxymethyl)-4-morpholinecarboxylic Acid Phenylmethyl Ester
• CAS NO: 500702-97-6
• Molecular Formula: C13H17NO4
• Molecular Weight: 251.27838
• Mol File: 500702-97-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 413.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.223±0.06 g/cm3(Predicted)
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: R-N-Cbz-2-Hydroxymethylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: R-N-Cbz-2-Hydroxymethylmorpholine(500702-97-6)
• EPA Substance Registry System: R-N-Cbz-2-Hydroxymethylmorpholine(500702-97-6)

Safety Data

• Hazardous Substances Data: 500702-97-6(Hazardous Substances Data)

Upstream product

• 40987-24-4 R,S-2-hydroxymethyl-4-benzylmorpholine 
• 501-53-1 benzyl chloroformate 
• 103003-01-6 morpholin-2-ylmethanol 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 868689-63-8 (S)-2,4-morpholinedicarboxylic acid 4-(1,1-dimethylethyl)ester 
• 1313584-92-7 (S)-2-(hydroxymethyl)morpholine hydrochloride 
• 144053-98-5 (R)-morpholin-2-ylmethanol hydrochloric acid salt 

Downstream Products

• 135782-22-8 Morpholine-2,4-dicarboxylic acid 4-benzyl ester 2-methyl ester 

Relevant articles and documents

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER

The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.

COMPOUNDS

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).